--- 
marp: true
theme: default
paginate: true
title: Medicinal Chemistry of Benzodiazepine Sedative-Hypnotics
footer: "PHA 548 ‚Äì Hampton University"
---

# üß¨ Medicinal Chemistry of Benzodiazepine Sedative-Hypnotics
**Course:** PHA 548 Pharmacology & Medicinal Chemistry  
**Instructor:** Sidney Bolden, Jr., Ph.D.


---

## üéØ Learning Objectives

By the end of this lecture, you will be able to:

1. Explain benzodiazepine interaction at the GABAA Œ±-Œ≥ interface  
2. Analyze SAR driving affinity, selectivity, and potency  
3. Predict PK outcomes based on chemical modifications  
4. Evaluate structural innovation leading to remimazolam

---

## GABAA Receptors ‚Äî Target Overview
![GABAA binding site](figures/BZ_Allosteric_Binding.jpg)
- **Pentameric ligand-gated Cl‚Åª channel**
- Typical stoichiometry: **2Œ± + 2Œ≤ + 1Œ≥**
- Benzodiazepines bind at **Œ±‚ÄìŒ≥ subunit interface**
- ‚Üë **frequency** of GABA-dependent channel openings  
- **Require GABA present** (safety advantage vs barbiturates)

---

### Œ± Subunit Pharmacology

| Œ± Subunit | Functional Outcome |
|----------|-------------------|
| Œ±1 | Sedation, amnesia, anticonvulsant |
| Œ±2 / Œ±3 | Anxiolysis, muscle relaxation |
| Œ±5 | Cognitive/memory effects |

---

## Essential Benzodiazepine Pharmacophore 

![Backbone](figures/BZ_backbone.jpg)

*5-phenyl-1,4-benzodiazepine-2-one backbone**

- Ring A: C7 **electronegative** group  
- Ring B: N1‚ÄìC2 **carbonyl** (H-bond anchor)  
- Ring C: **phenyl ring** (œÄ-stacking)

---
## Sedative-Hypnotic Benzodiazepines ##

![SH-BZDs](figures/BZ_Sedative-hypnotic.jpg)
* Benzodiazepine backbone indicative for Sedative-Hypnotic application (Foye Fig. 12.6)*

---

## SAR ‚Äî What Matters Most

| Site | Required Feature | Effect |
|------|-----------------|-------|
| C7 (Ring A) | Electronegative Cl/Br/NO‚ÇÇ | ‚Üë potency/affinity |
| C5 phenyl | Aromatic & planar | Required for agonism |
| o-Halogens | ‚Üë lipophilicity | ‚Üë BBB penetration |
| p-Substitution | Bulky groups disfavored | ‚Üì binding ‚Üí inactive |
| C3-OH | Conjugation site | ‚Üì t¬Ω (faster clearance) |
| Triazolo/imidazo | Fused ring | ‚Üë potency; ‚Üì oxidation |
| Ester appendage | Soft drug design | Ultra-short acting |

---

### Key SAR Visual Theme

> Medicinal chemistry controls:  
> **duration** ‚Ä¢ **distribution** ‚Ä¢ **safety profile**

---

## SAR ‚Üí PK Case Examples

**Flurazepam**  
- N-alkyl chain prone to **CYP3A4 N-dealkylation**  
- Multiple **long-acting** metabolites accumulate

---

## CYP Oxidation ‚Äî Classical BZD Metabolism

![Flurazepam metabolism](figures/flurazepam_metabolism.jpg)

*Long-acting metabolites ‚Üí residual sedation*
*Slow elimination of multiple active metabolites*
*Residual hypnotic effects, including excessive daytime drowsiness and over-sedation as well as cognitive decline and confusion, are common and clinically relevant adverse effects.*
---

**Temazepam circumvents phase 1 metabolism**  
![Temazepam metabolism](figures/Temazepam_metabolism.jpg)


- **C3-OH** ‚Üí Phase II glucuronidation  (O-glucuronidation)
- **Rapid** elimination  

---

### Phase II Conjugation Pathway

![Temazepam glucuronidation](figures/Temazepam_metabolism.jpg)
*Direct conjugation bypasses CYP450-dependent oxidation*

---

### Triazolobenzodiazepines SAR Advantage
** Estazolam and Triazolam **
*Estazolam Metabolism *


![Triazolo protection](figures/estazolam_metabolism.jpg)

*Fused ring blocks oxidative liability ‚Üí shorter duration*
*1,4-triazolo ring blocks (steric hindrance) oxidative metabolism typical of the benzodiazepines*
*Estazolam metabolites have weak GABAA pharmacological activity*

---

## PK & Metabolism Comparison

![PK Table (Foye Table 12.2)](figures/table_12.2.jpg)

---

### Table 12.2 ‚Äî Rebuilt for Accessibility

| Drug | Key SAR Feature | Metabolism Route | PK Outcome |
|------|----------------|-----------------|------------|
| **Flurazepam** | N-alkyl chain | CYP3A4 | Long-acting metabolites |
| **Quazepam** | Very lipophilic | CYP3A4/2C9 | Accumulation risk |
| **Estazolam** | Triazolobenzodiazepine | CYP3A4 | Intermediate duration |
| **Triazolam** | Compact structure | Oxidation ‚Üí conjugation | Short acting |
| **Temazepam** | C3-OH | Direct glucuronidation | Rapid clearance |
| **Remimazolam** | Ester appendage | Esterase hydrolysis | Ultra-short duration |

---

## Remimazolam ‚Äî Modern Medicinal Chemistry

![Remimazolam](figures/Remimazolam-metabolism.jpg)
*Soft drug designed for procedural control*

- Carboxylesterase hydrolysis ‚Üí inactive metabolite  
- Minimal CYP involvement ‚Üí fewer interactions  
- Predictable sedation onset/offset

---

## Structural Prediction Exercise

For each change, predict:

1Ô∏è‚É£ Binding effect  
2Ô∏è‚É£ Duration effect  

- Remove **C7-Cl**  
- Add **para bulky group**  
- Add **C3-OH**  
- Fuse **triazole ring**  
- Add **ester (soft drug)**  

*Discuss in pairs ‚Üí class review*

---

## Key Takeaways

- BZDs modulate GABA **frequency** (not duration)
- SAR directly shapes **PK & safety**
- Remimazolam = **soft-drug evolution**

---

# Questions?

Thank you!  
Next: Non-BZD GABAA-modulating hypnotics (Z-drugs).
